In the early clinical development of an anti-PD-1 antibody, the PD-L1 IHC analysis of tumor biopsies suggested a relationship between PD-L1 expression on tumor cells and an objective response to PD-1 pathway therapy. This evidence concerns the gene CD274 and neoplasm.